Onco-hematology
Defining the optimal total number of chemotherapy courses in younger patients with Acute Myeloid Leukemia: A comparison of 3 vs. 4 courses
19 Feb, 2021 | 02:06h | UTCDefining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Optimal Number of Treatment Courses Explored in Younger Patients with AML – CancerNetwork
Commentary on Twitter
What is the optimal number of chemotherapy courses in younger patients with acute myeloid leukemia (AML)? This study evaluates 3 vs 4 courses https://t.co/peC7Xo3BbX #leusm #JCO pic.twitter.com/OGChNkYS0X
— ASCO Publications (@ASCO_pubs) January 6, 2021
Short review: Acute CV complications of hematopoietic stem cell transplantation
18 Feb, 2021 | 02:40h | UTCAcute CV Complications of Hematopoietic Stem Cell Transplantation – American College of Cardiology
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL
9 Feb, 2021 | 00:39h | UTCCommentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)
Commentary on Twitter
Total body irradiation or chemotherapy conditioning in childhood acute lymphoblastic leukemia (ALL) — outcomes suggest there's still a role for TBI https://t.co/ICTC0iEGN8 #leusm #pedonc #pedcsm #JCO pic.twitter.com/xARMBlSeni
— ASCO Publications (@ASCO_pubs) December 26, 2020
Patients with lymphoma receiving B-Cell–depleting therapies may be at greater risk for persistent COVID-19 infection
9 Feb, 2021 | 01:14h | UTCRelated: Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection – The ASCO Post
See also: Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients — Plus: Active chemo treatment may not be a COVID risk factor – MedPage Today (free registration required)
Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer
7 Feb, 2021 | 20:45h | UTCCommentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive
Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease
26 Jan, 2021 | 00:35h | UTCDipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay